Literature DB >> 24981363

Tackling the cancer stem cells - what challenges do they pose?

Diwakar R Pattabiraman1, Robert A Weinberg2.   

Abstract

Since their identification in 1994, cancer stem cells (CSCs) have been objects of intensive study. Their properties and mechanisms of formation have become a major focus of current cancer research, in part because of their enhanced ability to initiate and drive tumour growth and their intrinsic resistance to conventional therapeutics. The discovery that activation of the epithelial-to-mesenchymal transition (EMT) programme in carcinoma cells can give rise to cells with stem-like properties has provided one possible mechanism explaining how CSCs arise and presents a possible avenue for their therapeutic manipulation. Here we address recent developments in CSC research, focusing on carcinomas that are able to undergo EMT. We discuss the signalling pathways that create these cells, cell-intrinsic mechanisms that could be exploited for selective elimination or induction of their differentiation, and the role of the tumour microenvironment in sustaining them. Finally, we propose ways to use our current knowledge of the complex biology of CSCs to design novel therapies to eliminate them.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24981363      PMCID: PMC4234172          DOI: 10.1038/nrd4253

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  253 in total

1.  Expression of novel surface antigens on early hematopoietic cells.

Authors:  H J Bühring; M Seiffert; T A Bock; S Scheding; A Thiel; A Scheffold; L Kanz; W Brugger
Journal:  Ann N Y Acad Sci       Date:  1999-04-30       Impact factor: 5.691

Review 2.  The ins and outs of the epithelial to mesenchymal transition in health and disease.

Authors:  M Angela Nieto
Journal:  Annu Rev Cell Dev Biol       Date:  2011-07-08       Impact factor: 13.827

Review 3.  Regulatory networks defining EMT during cancer initiation and progression.

Authors:  Bram De Craene; Geert Berx
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

4.  A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells.

Authors:  Hui Song; Renxiao Wang; Shaomeng Wang; Jiayuh Lin
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-21       Impact factor: 11.205

5.  Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

Authors:  Silvia Buonamici; Juliet Williams; Michael Morrissey; Anlai Wang; Ribo Guo; Anthony Vattay; Kathy Hsiao; Jing Yuan; John Green; Beatriz Ospina; Qunyan Yu; Lance Ostrom; Paul Fordjour; Dustin L Anderson; John E Monahan; Joseph F Kelleher; Stefan Peukert; Shifeng Pan; Xu Wu; Sauveur-Michel Maira; Carlos García-Echeverría; Kimberly J Briggs; D Neil Watkins; Yung-mae Yao; Christoph Lengauer; Markus Warmuth; William R Sellers; Marion Dorsch
Journal:  Sci Transl Med       Date:  2010-09-29       Impact factor: 17.956

6.  Distinct expression levels and patterns of stem cell marker, aldehyde dehydrogenase isoform 1 (ALDH1), in human epithelial cancers.

Authors:  Shan Deng; Xiaojun Yang; Heini Lassus; Shun Liang; Sippy Kaur; Qunrui Ye; Chunsheng Li; Li-Ping Wang; Katherine F Roby; Sandra Orsulic; Denise C Connolly; Youcheng Zhang; Kathleen Montone; Ralf Bützow; George Coukos; Lin Zhang
Journal:  PLoS One       Date:  2010-04-21       Impact factor: 3.240

7.  GDC-0449-a potent inhibitor of the hedgehog pathway.

Authors:  Kirk D Robarge; Shirley A Brunton; Georgette M Castanedo; Yong Cui; Michael S Dina; Richard Goldsmith; Stephen E Gould; Oivin Guichert; Janet L Gunzner; Jason Halladay; Wei Jia; Cyrus Khojasteh; Michael F T Koehler; Karen Kotkow; Hank La; Rebecca L Lalonde; Kevin Lau; Leslie Lee; Derek Marshall; James C Marsters; Lesley J Murray; Changgeng Qian; Lee L Rubin; Laurent Salphati; Mark S Stanley; John H A Stibbard; Daniel P Sutherlin; Savita Ubhayaker; Shumei Wang; Susan Wong; Minli Xie
Journal:  Bioorg Med Chem Lett       Date:  2009-08-15       Impact factor: 2.823

8.  Phorbol ester-stimulated phosphorylation of PU.1: association with leukemic cell growth inhibition.

Authors:  J O Carey; K J Posekany; J E deVente; G R Pettit; D K Ways
Journal:  Blood       Date:  1996-05-15       Impact factor: 22.113

9.  Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas.

Authors:  Arnout G Schepers; Hugo J Snippert; Daniel E Stange; Maaike van den Born; Johan H van Es; Marc van de Wetering; Hans Clevers
Journal:  Science       Date:  2012-08-01       Impact factor: 47.728

Review 10.  Acute promyelocytic leukemia.

Authors:  R P Warrell; H de Thé; Z Y Wang; L Degos
Journal:  N Engl J Med       Date:  1993-07-15       Impact factor: 91.245

View more
  375 in total

Review 1.  The influence of subclonal resistance mutations on targeted cancer therapy.

Authors:  Michael W Schmitt; Lawrence A Loeb; Jesse J Salk
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

2.  Anti-Müllerian Hormone Signaling Regulates Epithelial Plasticity and Chemoresistance in Lung Cancer.

Authors:  Tim N Beck; Vladislav A Korobeynikov; Alexander E Kudinov; Rachel Georgopoulos; Nehal R Solanki; Magda Andrews-Hoke; Timothy M Kistner; David Pépin; Patricia K Donahoe; Emmanuelle Nicolas; Margret B Einarson; Yan Zhou; Yanis Boumber; David A Proia; Ilya G Serebriiskii; Erica A Golemis
Journal:  Cell Rep       Date:  2016-07-07       Impact factor: 9.423

Review 3.  Chemical Disruption of Wnt-dependent Cell Fate Decision-making Mechanisms in Cancer and Regenerative Medicine.

Authors:  L Lum; C Chen
Journal:  Curr Med Chem       Date:  2015       Impact factor: 4.530

4.  Photocontrolled miR-148b nanoparticles cause apoptosis, inflammation and regression of Ras induced epidermal squamous cell carcinomas in mice.

Authors:  Yiming Liu; Jacob T Bailey; Mohammad Abu-Laban; Shue Li; Cong Chen; Adam B Glick; Daniel J Hayes
Journal:  Biomaterials       Date:  2020-06-22       Impact factor: 12.479

5.  Harnessing the DNA Dye-triggered Side Population Phenotype to Detect and Purify Cancer Stem Cells from Biological Samples.

Authors:  Maximilian Boesch; Elisabeth Hoflehner; Dominik Wolf; Guenther Gastl; Sieghart Sopper
Journal:  J Vis Exp       Date:  2017-05-10       Impact factor: 1.355

Review 6.  TGF-beta signaling in cancer: post-transcriptional regulation of EMT via hnRNP E1.

Authors:  Breege V Howley; Philip H Howe
Journal:  Cytokine       Date:  2018-02-01       Impact factor: 3.861

7.  Malignant Pleural Effusion and ascites Induce Epithelial-Mesenchymal Transition and Cancer Stem-like Cell Properties via the Vascular Endothelial Growth Factor (VEGF)/Phosphatidylinositol 3-Kinase (PI3K)/Akt/Mechanistic Target of Rapamycin (mTOR) Pathway.

Authors:  Tao Yin; Guoping Wang; Sisi He; Guobo Shen; Chao Su; Yan Zhang; Xiawei Wei; Tinghong Ye; Ling Li; Shengyong Yang; Dan Li; Fuchun Guo; Zeming Mo; Yang Wan; Ping Ai; Xiaojuan Zhou; Yantong Liu; Yongsheng Wang; Yuquan Wei
Journal:  J Biol Chem       Date:  2016-10-18       Impact factor: 5.157

8.  Induction of the intestinal stem cell signature gene SMOC-2 is required for L1-mediated colon cancer progression.

Authors:  A Shvab; G Haase; A Ben-Shmuel; N Gavert; T Brabletz; S Dedhar; A Ben-Ze'ev
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

9.  RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.

Authors:  Robert A Jones; Tyler J Robinson; Jeff C Liu; Mariusz Shrestha; Veronique Voisin; YoungJun Ju; Philip E D Chung; Giovanna Pellecchia; Victoria L Fell; SooIn Bae; Lakshmi Muthuswamy; Alessandro Datti; Sean E Egan; Zhe Jiang; Gustavo Leone; Gary D Bader; Aaron Schimmer; Eldad Zacksenhaus
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

Review 10.  Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review.

Authors:  Shijie Sheng; M Margarida Bernardo; Sijana H Dzinic; Kang Chen; Elisabeth I Heath; Wael A Sakr
Journal:  Cancer Metastasis Rev       Date:  2018-12       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.